In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Noninvasive Prenatal Screening: Battleground In Diagnostics Innovation

Executive Summary

Four companies have brought noninvasive prenatal testing to the market within the past two years. Its dramatic, rapid uptake has triggered a backlash among many geneticists, who fear the consequences of a poorly understood – and overhyped – technology.

Advertisement

Related Content

The A-List: The Trend-Shaping Series A Financings Of 2014
2013: The Year In Diagnostics
Illumina’s Unique Leverage In NIPT
Illumina Stakes A Claim In NIPT Market With $450-Million Acquisition Of Verinata
Genomics Enters The Neonatal ICU
Molecular Diagnostics Ushers In New Era Of Prenatal Testing

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel